Allergy Diseases on the Rise in Sweden, Treatment Access Varies Widely
Allergy diseases are increasingly prevalent and have become some of the most common chronic conditions. While research advancements offer effective treatments allowing many to live with fewer troubles for extended periods, new figures reveal a significant disparity in treatment access across different regions of Sweden. Health organizations are urging regional authorities to promptly address and level out these differences.
Three million Swedes are affected by pollen allergy, with approximately one million experiencing asthma and a similar number suffering from atopic eczema. For many, these conditions impose considerable restrictions on daily life and severely impair their quality of life.
However, ongoing research provides a beacon of hope. Recent progress, such as the development of allergy vaccination for pollen allergy, can lead to a decrease or even complete disappearance of symptoms.
A survey conducted by the Asthma and Allergy Association indicates that access to allergy vaccination is currently low and varies geographically. For instance, Halland County reported 50 patients per 10,000 inhabitants receiving allergy vaccination in 2023, while Kalmar County had a corresponding figure of only 34 patients per 10,000 inhabitants.
Beyond the individual suffering,the rising number of pollen allergies incurs substantial costs for both affected individuals and society. A new fact sheet from the Foundation Research! Sweden highlights that the annual societal cost of allergic rhinitis alone amounts to SEK 12 billion in Sweden. the primary driver of this cost is the inadequacy of common symptom-relieving medications, which hinders individuals’ ability to perform effectively and cope with the demands of school or work.
“Let’s capitalize on research progress to enhance the health of Sweden’s population,” stated Anna Nilsson Vindefjärd, founder and secretary general of research! Sweden. Mikaela Odemyr, Chairman of the Asthma and Allergy Association, and
